

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



百信集团
PASHUN GROUP

Pa Shun Pharmaceutical International Holdings Limited

百信藥業國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 574)

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The Board of Directors (the “**Board**”) of Pa Shun Pharmaceutical International Holdings Limited (the “**Company**”) announces that the principal place of business of the Company in Hong Kong will be changed to Unit D-F, 15/F Neich Tower, 128 Gloucester Road, Wan Chai, Hong Kong with effect from 11 October 2016.

By order of the Board

Pa Shun Pharmaceutical International Holdings Limited

Mr. Chen Yenfei

Chairman

Hong Kong, 4 October 2016

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yenfei, Mr. Shen Shun, Mr. Zhou Jian; the non-executive directors of the Company are Mr. Li Ho Tan, Mr. Zhang Xiongfeng and Mr. Masahiro Honna; and the independent non-executive directors of the Company are Mr. Liu Liangzhong, Mr. Wong Tak Shing and Mr. Min Feng.